Provisional figures on participation in the National Immunisation Programme According to RIVM’s registration system, at least 90% of babies have been vaccinated against mumps, measles and rubella (MMR).
Incidence of infections that cause gastrointestinal symptoms on the rise again In 2021, the incidence of enteric infections – which mainly cause gastrointestinal symptoms – was higher than in 2020, but still lower than before the coronavirus pandemic. This is the outcome of a study into enteric infections and pathogens transmitted from animals to humans.
Incorrect emission factors used for some farms included in list of top 100 ammonia emitters At the request of the Dutch House of Representatives, RIVM compiled a list of the 100 biggest ammonia emitters in the Netherlands. Recently, the underlying data used to compile this list were disclosed pursuant to a request under the Open Government Act.
RIVM creates overview of nitrogen monitoring in water in Europe At the behest of the European Parliament, the National Institute for Public Health and the Environment (RIVM) has formulated a report on how EU member states are dealing with European regulations on nitrogen in water (nitrate). Michel Looyenstein
New risk limits for PFAS in surface water The National Institute for Public Health and the Environment (RIVM) has derived new risk limits for PFAS in surface water. The guiding principle for these limits is that people should be able to consume fish sourced from surface water throughout their lives without ingesting excessive levels of PFAS.
RIVM formulates criteria for R&D of sustainable pharmaceuticals As part of an international research project, RIVM has formulated criteria for R&D of sustainable new pharmaceuticals. These GREENER criteria are an important first step to develop pharmaceuticals that do not impact the environment..
Side effect reports National Immunisation Programme 2021 Last year, the Netherlands Pharmacovigilance Centre Lareb received 1,462 reports of possible side effects from vaccines administered under the National Immunisation Programme. As was the case in previous years, no new, disconcerting side effects have
BA.2.75 variant found in the Netherlands The BA.2.75 variant of the coronavirus SARS-CoV-2 has now also been found in the Netherlands. The variant was detected in a sample from 26 June 2022 taken in the region of Noordoost-Gelderland.
Participation in National Immunisation Programme shows slight decrease Participation in the National Immunisation Programme has fallen slightly, showing a decrease of 1 to 2 percentage points.
SARS-CoV-2 infections continue to rise Infections with the coronavirus SARS-CoV-2 in the Netherlands continued to rise this week. This increase can be seen in sewage surveillance and in the infections reported to the Municipal Public Health Services (GGDs).